Seegnal
Seegnal presents a paradigm shift in combating Adverse Drug Reactions and their impacts, including health consequences, economic repercussions in re-admissions and re-visits, and doctors' fatigue, as well as streamlining the prescription process at the point of care, by moving the industry from DDI standard (Drug to Drug Interaction) to a new Patient at the Core standard. The platform integrates seamlessly with any Electronic Medical Records (EMR) system to offer personalized medication recommendations, including Precision Medication, in real-time with an unparalleled accuracy rate of 98%. Seegnal’s Digital Co-Pilot presents the future of prescribing medications at the point of care.
Seegnal is currently seeking investment
Seegnal is seeking a growth-stage investment in the range of 1m-5m
What We Do
A clinical decision support engine that offers real-time patient-specific drug interaction solutions on a single screen, designed to prevent adverse drug reactions.
Seegnal's unique AAI manages alerts 24/7, ensuring clinicians are notified of critical changes in patient data.
Seegnal resolves drug-related problems by offering the best available therapy from the institution's drug repository.
Provides patients with dietary instructions and identifies symptoms from medication side effects automatically.
A patented feature that allows physicians to view and resolve alerts instantly on a clutter-free screen.
Enables clinicians to provide personalized medication recommendations based on genetic profiles.
Enhances existing EMR systems by integrating Seegnal's decision support capabilities.
Provides a virtual pharmacist to all clinicians at a fraction of the cost, maximizing value-based care savings and reducing medical malpractice claims.
Application Area
Show LessPsychological and Cognitive Health and Performance
Biologics
Diagnostics
Digital Health Technologies
Show LessServices
Key People
News & Updates
Discusses the use of Doxazosin in an 85-year-old elderly female and the associated risks.
Explores the use of Bezafibrate sustained release formulation in patients with impaired renal function.
Analyzes the common alerts for prescribing two medications belonging to the incretin family.
Seegnal's distributor in the UK, Digitals UK, has been awarded a framework contract by the UK government to sell Seegnal in the public sector.
Seegnal will present at the world's leading healthcare expo for innovation as part of the Israeli Export Institution booth.
Seegnal Poland has signed the first hospitals to pilot Seegnal and is waiting for more hospitals to join.
Leumit HMO has signed a 5-year renewal with Seegnal, upgrading to version 10.x to enhance functionality and support.